Clinical Trials

April 30, 2025

Could pirtobrutinib become a first-line CLL treatment? Learn how new research shows promise beyond BTK resistance for high-risk patients.

April 16, 2025

Understanding how ROR1-targeted therapies work—and whether they apply to your specific blood cancer type—can help you make more informed treatment decisions.

February 12, 2025

Explore recent updates on clinical trials investigating BTK degraders for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

October 01, 2024

Understanding CAR T-Cell Therapy and the Armored CAR T-Cell Trial

September 06, 2024

Learn how BTK degrader BGB-16673 can aid in managing CLL/SLL if you've previously taken BTK inhibitors and venetoclax.

August 23, 2024

Learn how zanubrutinib and venetoclax helped high-risk CLL patients with del(17p)/TP53 mutation as their first treatment from the SEQUOIA study.

July 17, 2024

Learn about cem-cel, a CAR T-cell therapy made from donor T-cells that may decrease T-cell exhaustion and is more quickly available than liso-cel (Breyanzi).

April 17, 2024

Dr. Inhye Ahn is conducting a clinical trial utilizing pirtobrutinib combined with obinutuzumab for CLL patients needing treatment for the first time.

April 15, 2024

Dr. Inhye Ahn from Dana-Farber Cancer Institute is conducting a clinical trial that administers a personalized vaccine for CLL called NeoVax. 

April 10, 2024

Learn about BTK degraders, a new type of CLL medicine in clinical trials that help overcome treatment resistance.